UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials

Supportive care in cancer, 2014-06, Vol.22 (6), p.1685-1697

2014

Volltextzugriff (PDF)

Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy

Journal of clinical oncology, 2005-04, Vol.23 (12), p.2822-2830

2005

Volltextzugriff (PDF)

The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group

Journal of clinical oncology, 2003-11, Vol.21 (22), p.4112-4119

2003

Volltextzugriff (PDF)

Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer

Breast cancer research and treatment, 2018-02, Vol.168 (1), p.159-168

2018

Volltextzugriff (PDF)

Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy

Cancer, 2005-10, Vol.104 (7), p.1548-1555

2005

Volltextzugriff (PDF)

A Phase 2 study of perifosine in advanced or metastatic breast cancer

Breast cancer research and treatment, 2008-03, Vol.108 (1), p.87-92

2008

Volltextzugriff (PDF)

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin–cyclophosphamide-based chemotherapy

Supportive care in cancer, 2011-06, Vol.19 (6), p.807-813

2011

Volltextzugriff (PDF)

Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis

Supportive care in cancer, 2018-08, Vol.26 (8), p.2519-2549

2018

Volltextzugriff (PDF)

Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings—a meta-analysis

Supportive care in cancer, 2016-05, Vol.24 (5), p.1941-1954

2016

Volltextzugriff (PDF)

Should palonosetron be a preferred 5-HT 3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis

Supportive care in cancer, 2018-08, Vol.26 (8), p.2519

2018

Volltextzugriff (PDF)

A Phase III Randomized, Double-Blind, Placebo-Controlled Study Evaluating Dextromethorphan Plus Slow-Release Morphine for Chronic Cancer Pain Relief in Terminally Ill Patients

Journal of pain and symptom management, 2007-04, Vol.33 (4), p.365-371

2007

Volltextzugriff (PDF)

Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC)

Supportive care in cancer, 2011-09, Vol.19 (9), p.1297-1302

2011

Volltextzugriff (PDF)

Should palonosetron be a preferred 5-HT.sub.3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis

Supportive care in cancer, 2018-08, Vol.26 (8), p.2519

2018

Volltextzugriff (PDF)

Chemotherapy-and cancer-related nausea and vomiting

Current oncology (Toronto), 2008-01, Vol.15 (Suppl 1), p.S4-9

Warr, D G

2008

Volltextzugriff (PDF)

Differential time course of action of 5-HT^sub 3^ and NK^sub 1^ receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC)

Supportive care in cancer, 2011-09, Vol.19 (9), p.1297

2011

Volltextzugriff (PDF)

Differential time course of action of 5-H[T.sub.3] and N[K.sub.1] receptor antagonists when used with highly and moderately emetogenic chemotherapy

Supportive care in cancer, 2011-09, Vol.19 (9), p.1297

2011

Volltextzugriff (PDF)

A phase III randomized, double-blind, placebo-controlled study evaluating dextromethorphan plus slow-release morphine for chronic cancer pain relief in terminally III patients

Journal of pain and symptom management, 2007, Vol.33 (4), p.365-371

2007

Volltextzugriff (PDF)

The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials

European journal of cancer (1990), 2005-06, Vol.41 (9), p.1278

2005

Volltextzugriff (PDF)

The oral NK 1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials

European journal of cancer (1990), 2005, Vol.41 (9), p.1278-1285

2005

Volltextzugriff (PDF)

Unconventional therapies for cancer: a refuge from the rules of evidence?

Canadian Medical Association journal (CMAJ), 1998-10, Vol.159 (7), p.801

1998

Volltextzugriff (PDF)

The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and omiting : Pooled data from 2 randomised, double-blind, placebo controlled trials

European journal of cancer (1990), 2005, Vol.41 (9), p.1278-1285

2005

Volltextzugriff (PDF)

Efficacy and safety of 1-day versus 3-day dexamethasone for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials

Journal of Hospital Management and Health Policy, 2018-05, Vol.2, p.25-25

2018

Volltextzugriff (PDF)

O-249 Evaluation of the efficacy and tolerability of the oral NK1 antagonist aprepitant for the prevention of chemotherapy induced nausea and vomiting: two randomized, double-blind, placebo controlled trials

Lung cancer (Amsterdam, Netherlands), 2003-08, Vol.41, p.S73-S73

2003

Volltextzugriff (PDF)

Hematopoietic Stem Cell Quiescence Promotes Error-Prone DNA Repair and Mutagenesis

Cell stem cell, 2010-08, Vol.7 (2), p.174-185

2010

Volltextzugriff (PDF)

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

The New England journal of medicine, 2019-02, Vol.380 (7), p.617-628

2019

Volltextzugriff (PDF)

1 – 25 von 79

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(70)
Mit Volltextzugriff
(70)

Publikationsform

Sprache

Englisch
(79)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials

Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy

The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group

Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer

Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy

A Phase 2 study of perifosine in advanced or metastatic breast cancer

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin–cyclophosphamide-based chemotherapy

Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis

Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings—a meta-analysis

Should palonosetron be a preferred 5-HT 3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis

A Phase III Randomized, Double-Blind, Placebo-Controlled Study Evaluating Dextromethorphan Plus Slow-Release Morphine for Chronic Cancer Pain Relief in Terminally Ill Patients

Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC)

Should palonosetron be a preferred 5-HT.sub.3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis

Chemotherapy-and cancer-related nausea and vomiting

Differential time course of action of 5-HT^sub 3^ and NK^sub 1^ receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC)

Differential time course of action of 5-H[T.sub.3] and N[K.sub.1] receptor antagonists when used with highly and moderately emetogenic chemotherapy

A phase III randomized, double-blind, placebo-controlled study evaluating dextromethorphan plus slow-release morphine for chronic cancer pain relief in terminally III patients

The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials

The oral NK 1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials

Unconventional therapies for cancer: a refuge from the rules of evidence?

The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and omiting : Pooled data from 2 randomised, double-blind, placebo controlled trials

Efficacy and safety of 1-day versus 3-day dexamethasone for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials

O-249 Evaluation of the efficacy and tolerability of the oral NK1 antagonist aprepitant for the prevention of chemotherapy induced nausea and vomiting: two randomized, double-blind, placebo controlled trials

Hematopoietic Stem Cell Quiescence Promotes Error-Prone DNA Repair and Mutagenesis

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Suchergebnisse filtern